DNA RNA and Cells
17 October 2014
Adaptimmune Announces Interim Results from Pilot Trial of its Engineered NY-ESO T Cells Targeting Synovial Sarcoma16 October 2014
Promethera Biosciences receives approval in Belgium to enroll patients in the imminent HEP002 Phase IIb/III clinical trial16 October 2014
Cellular Biomedicine Group Launches Pre-Clinical Research Study for Chronic Obstructive Pulmonary Disease (COPD)16 October 2014
Novartis announces CTL019 data published in NEJM demonstrating efficacy in certain patients with acute lymphoblastic leukemia (ALL)14 October 2014
Idera Pharmaceuticals Expands Pipeline by Initiating Clinical Development of Proprietary TLR Antagonist Candidate IMO-920014 October 2014
Alnylam Presents New Clinical and Pre-Clinical Data on RNAi Therapeutics at 10th Oligonucleotide Therapeutics Society (OTS) Meeting14 October 2014
bluebird bio Announces First Patient with Sickle Cell Disease Transplanted with LentiGlobin Gene Therapy13 October 2014
Cardio3 Biosciences Receives Authorization to Enroll Patients in Switzerland in its Phase III Clinical Trial Chart-110 October 2014
Prosensa begins NDA submission to the FDA for exon-skipping drug drisapersen to treat Duchenne muscular dystrophy10 October 2014
Isis Pharmaceuticals Reports Data From ISIS-SMN Rx Phase 2 Studies in Infants and Children With Spinal Muscular Atrophy9 October 2014
Study Shows Rebiotix Microbiota-based Drug Candidate Targeted at Recurrent C. difficile Infection is Highly Effective6 October 2014
Nitto: New Anti-Fibrosis Drug With Molecular Targeting DDS Starts Phase-1B Dosing for Cirrhosis Patients6 October 2014
AnGes Starts Global Phase III Clinical Trials of Collategene(R) for Critical Limb Ischemia1 October 2014
Alnylam Initiates EXPLORE, a Prospective Observational Study of Patients with Hepatic Porphyrias1 October 2014
Mesoblast Partner JCR Pharmaceuticals Files for Marketing Approval of the First Allogeneic Stem Cell Product in Japan30 September 2014
Sarepta Therapeutics Announces Favorable Safety Results from Phase I Clinical Study of Influenza Drug Candidate26 September 2014
Adaptimmune secures $104 million in Series A FinancingNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports